Cytokinetics (CYTK) Revenue (2016 - 2025)
Historic Revenue for Cytokinetics (CYTK) over the last 16 years, with Q4 2024 value amounting to -$8.9 million.
- Cytokinetics' Revenue fell 63456.94% to -$8.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$7.4 million, marking a year-over-year decrease of 19815.41%. This contributed to the annual value of -$37.7 million for FY2024, which is 60067.73% down from last year.
- Per Cytokinetics' latest filing, its Revenue stood at -$8.9 million for Q4 2024, which was down 63456.94% from $463000.0 recorded in Q3 2024.
- Cytokinetics' Revenue's 5-year high stood at $89.0 million during Q2 2022, with a 5-year trough of -$12.6 million in Q4 2020.
- Over the past 5 years, Cytokinetics' median Revenue value was $2.2 million (recorded in 2022), while the average stood at $9.3 million.
- As far as peak fluctuations go, Cytokinetics' Revenue soared by 302937.04% in 2022, and later tumbled by 63456.94% in 2024.
- Quarter analysis of 5 years shows Cytokinetics' Revenue stood at -$12.6 million in 2020, then skyrocketed by 417.88% to $40.1 million in 2021, then plummeted by 95.12% to $2.0 million in 2022, then fell by 14.56% to $1.7 million in 2023, then plummeted by 634.57% to -$8.9 million in 2024.
- Its Revenue was -$8.9 million in Q4 2024, compared to $463000.0 in Q3 2024 and $249000.0 in Q2 2024.